Sudden death in cardiology


Authors: L. Křivan
Published in: Kardiol Rev Int Med 2012, 14(3): 176-181
Category:

Overview

Despite of improvement in diagnostics and treatment of cardiac di­seases sudden cardiac death still remains a substantial problem. Implantable cardioverter-defibrillators (ICD) have been used in sudden death prevention for three decades. A significant turn-over appeared in last 10 years. The number of secondary prevention ICD implantations remains nearly stable whereas number of ICD recipients from primary preventive reasons still increases. With enlarging patient’s popu­lation indicated for implantation the efficacy of ICD declines and the costs rise drama­tically. An objective of this paper is to summarize ICD indication criteria in context with the multicentric studies results. An article tends to define a profile of the patients who have no profit from ICD implantation although fulfilling primary prevention criteria.

Keywords:
implantable cardioverter-defibrillator – sudden cardiac death – congestive heart failure – primary preventive ICD implantation


Sources

1. Passman R, Kadish A. Sudden death prevention with implantable devices. Circulation 2007; 116: 561–571.

2. Zimerman LI. Cardioverter-defibrillator in the primary prevention of sudden death: for all or for a few? Arq Bras Cardiol 2008; 1: 63–64.

3. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997; 337: 1576–1583.

4. Kuck KH, Cappato R, Siebels J et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study of Hamburg (CASH). Circulation 2000; 102: 748–754.

5. Connolly SJ, Gent M, Roberts RS et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297–1302.

6. Leyva F, Fernandez Lozano I, Morgan J. Cardioverter-defibrillators: a cost or an investment? Europace 2011; 13 (Suppl 2): ii25–ii31.

7. Dorian P, Talajic M, Tang A. Implantable cardioverter defibrillators for the prevention of sudden death. Can J Cardiol 2005; 21 (Suppl A): 31A–36A.

8. Moss AJ, Hall WJ, Cannom DS et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335: 1933–1940.

9. Moss AJ, Zareba W, Hall WJ et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877–883.

10. Bardy GH, Lee KL, Mark DB et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter--defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225–237.

11. Bänsch D, Antz M, Boczor S et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002; 105: 1453–1458.

12. Wijetunga M, Strickberger SA. Amiodarone Versus Imlapntable Defibrillator Randomized Trial (AMIOVIRT): background, rationale, design, methods, results and implications. Card Electrophysiol Rev 2003; 7: 452–456.

13. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997; 337: 1569–1575.

14. Connolly SJ, Dorian P. DINAMIT investigators. Randomized trial of ICD After recent acute myocardial infarction: DINAMIT. Can J Cardiol 2004; 20 (Suppl D): 146D.

15. Táborský M. Arytmie a trvalá kardiostimulace. Zásady pro implantace kardiostimulátorů, implantabilních kardioverterů-defibrilátorů a systémů pro srdeční resynchronizační léčbu 2009. Cor Vasa 2009; 51: 602–614.

16. Křivan L. Primární prevence náhlé srdeční smrti – ICD pro všechny s dysfunkcí srdeční komory? Cor Vasa 2010; 52: 35–35.

17. Carrim ZI, Khan AA, Aslam S. Primary prevention of fatal ventricular arrhythmias with implantable cardio­verter-defibrillator therapy – an analysis of implications based on MADIT II criteria. Mcgill J M 2006; 9: 14–18.

18. Al-Khatib SL, Hellkamp A, Curtis J et al. Non--evidence-based ICD implantation in the United States. JAMA 2011; 305: 43–49.

19. Ding L, Hua W, Niu H et al. Primary prevention of sudden cardiac death using implantable cardioverter defibrillators. Europace 2008; 10: 1034–1041.

20. Henyan NH, White CM, Gillespie EL et al. The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death. J Intern Med 2006; 260: 467–473.

21. Russo AM, Poole JE, Mark DB et al. Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial. J Cardiovasc Electrophysiol 2008; 19: 720–724.

22. Sweeney MO, Hellkamp AS, Ellenbogen KA et al. Reduced ejection fraction, sudden cardiac death, and heart failure death in the Mode Selection Trial (MOST): implications for device selection in elderly patients with sinus node disease. J Cardiovasc Electrophysiol 2008; 19: 1160–1166.

23. Setoguchi S, Nohria A, Rassen JA et al. Maximum potential benefit of implantable defibrillators in preventing sudden death after hospital admission because heart failure. CMAJ 2009; 180: 611–616.

24. Boriani G. Cardioverter defibrillators in primary prevention of sudden cardiac death: a cost or an investment? Value Health 2007; 10: 1–2.

25. Huang DT, Sesselberg HW, McNitt S et al. Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy. J Cardiovasc Electrophysiol 2007; 18: 833–838.

26. Goldenberg I, Vyas AK, Hall WJ et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008; 51: 288–296.

27. Tung R, Swerdlow CD. Refining patient selection for primary prevention implantable cardioverter-defibrillator therapy: reeling in a net cast too widely. Circulation 2009; 120: 825–827.

28. Křivan L, Kozák M, Sepši M et al. Analýza a srovnání souborů nositelů implantabilního kardioverteru-defibrilátoru v primární a sekundární prevenci. Vnitř Lék 2010; 56: 99–105.

29. Moss AJ. Implantable cardioverter defibrillator therapy: the sickest patients benefit the most. Circulation 2000; 101: 1638–1640.

30. Dorian P. Effective and efficient use of implantable defibrillators: sometimes it’s over when it’s over. CMAJ 2009; 180: 599–600.

31. Jolly S, Dorian P, Alter DA. The impact of implantable cardiac defibrillators for primary prophylaxis in the community: baseline risk and clinically meaningful benefits. J Eval Clin Pract 2006; 12: 190–195.

32. Gehi A, Haas D, Fuster V. Primary prophylaxis with the implantable cardioverter-defibrillator: the need for improved risk stratification. JAMA 2005; 294: 958–960.

33. Barthel P, Bauer A, Schneider R et al. Prolonged QRS duration is an independent risk predictor after acute myocardial infarction. PACE 2003; 26: 943.

34. Kalahasti V, Nambi V, Martin DO et al. QRS duration and prediction of mortality in patients undergoing risk stratification for ventricular arrhythmias. Am J Cardiol 2003; 92: 798–803.

35. Zipes PD, Camm AJ, Borggrefe M et al. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48: e247–e346.

36. Bloomfield DM, Bigger JT, Steinman RC et al. Microvolt T-wave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction. J Am Coll Cardiol 2006; 47: 456–463.

37. Chan PS, Stein K, Chow T et al. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population. J Am Coll Cardiol 2006; 48: 112–121.

38. Hjalmarson A. Prevention of sudden cardiac death with beta blockers. Clin Cardiol 1999; 22 (Suppl 5): V11–V15.

39. Lane ER, Cowie MR, Chow AW. Prediction and prevention of sudden cardiac death in heart failure. Heart 2005; 91: 674–680.

40. Bundkirchen A, Schwinger RH. Epidemiology and economic burden of chronic heart failure. Eur Heart J 2004; 6 (Suppl D): D57–D60.

41. Bunch JT, Hohnloser SH, Gersh BJ. Mechanisms of sudden cardiac death in myocardial infarction survivors: insights from the randomized trials of implantable cardioverter-defibrillators. Circulation 2007; 115: 2451–2457.

Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account